<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680186</url>
  </required_header>
  <id_info>
    <org_study_id>1160.46</org_study_id>
    <secondary_id>2007-002631-86</secondary_id>
    <nct_id>NCT00680186</nct_id>
  </id_info>
  <brief_title>Phase III Study Testing Efficacy &amp; Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)</brief_title>
  <acronym>RE-COVER II</acronym>
  <official_title>A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general aim of this study is to determine the comparative safety and efficacy of
      dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN)
      to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute
      symptomatic VTE.

      The primary objective is to investigate the efficacy of dabigatran compared to warfarin
      during the 6 month treatment period. The investigation of other selected efficacy aspects and
      safety are regarded as secondary objective of this trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE</measure>
    <time_frame>For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)</time_frame>
    <description>All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Symptomatic VTE and All Deaths</measure>
    <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
    <description>VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Symptomatic DVT</measure>
    <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
    <description>Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Symptomatic Non-fatal PE</measure>
    <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
    <description>Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Due to VTE</measure>
    <time_frame>From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)</time_frame>
    <description>VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died (Any Cause)</measure>
    <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
    <description>Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Symptomatic Fatal and Non-fatal PE</measure>
    <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
    <description>Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MBE, MBE and/or CRBE, and Any Bleeding Events</measure>
    <time_frame>From first intake of study drug to last intake of study drug + 6 days washout</time_frame>
    <description>Major bleeding events (MBE) are defined as
Fatal bleeding
Symptomatic bleeding in a critical area or organ
Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells
Clinically-relevant bleeding events (CRBE) are defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding
gingival bleeding &gt;5 min
leading to hospitalisation and / or requiring surgical treatment
leading to a transfusion of &lt;2 units of whole blood or red cells
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Coronary Syndrome (ACS)</measure>
    <time_frame>From first intake of study drug to last contact date</time_frame>
    <description>Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>From first intake of study drug to last intake of study drug + 6 days washout</time_frame>
    <description>Frequency of patients with possible clinically significant abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2589</enrollment>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate (150mg bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin (INR 2.0-3.0)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>PRN (to maintain a target INR of 2.0-3.0)</description>
    <arm_group_label>Warfarin (INR 2.0-3.0)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>150mg bid</description>
    <arm_group_label>Dabigatran etexilate (150mg bid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Acute symptomatic uni- or bilateral Deep Vein Thrombosis (DVT) of the leg involving
             proximal veins, and/or Pulmonary Embolism (PE)

          -  Male or female, being 18 years of age or older

          -  Written informed consent for study participation

        Exclusion criteria:

          -  Persistent symptoms of VTE

          -  PE requiring urgent intervention

          -  Use of vena cava filter

          -  Contraindications to anticoagulant therapy

          -  Allergy to study medications

          -  Elevated Aspartate-aminotransferase (AST) or Alanine-aminotransferase (ALT) &gt; 3x Upper
             Limit of Normal (ULN) or known liver disease expected to have an impact on survival

          -  Severe renal impairment

          -  Patients considered unsuitable for inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.46.01073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.01062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.61007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.61006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.61005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasília</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São Bernardo do Campo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.55020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.35901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.35906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.02020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.86020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Litomerice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novy Jicin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrava-Vitkovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Teplice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.45008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.45009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3315A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Roche-Sur-Yon cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3315B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Roche-Sur-Yon cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3313A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3316A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3316B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3303E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3303F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3303G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3303H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Priest En Jarez Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Priest En Jarez Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.36010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.36011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ludhiana</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vadodra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97212 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>DN Lower Galillee</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97211 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>KfarSaba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petah Tiqwa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Hashomer, Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.97201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.39015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.39012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.39013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vittorio Veneto (TV)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyunggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelantan Kota Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.60003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melaka</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.60004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pahang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.60002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.31017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.31013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.31015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.64004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.64003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grafton Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Otahuhu Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takapuna Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.65001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.65002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.65003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bryanston</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.27013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.27014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kempton Park</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.27015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morningside</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.27012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plumstead</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sunninghill</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cartagena. Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.34015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.34014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabadell - barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.46010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kristianstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.46008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.88607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>ChangHua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.88604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.88606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.88608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.88609 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.66007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.66010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.66001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.66004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muang Nakhonratchasima</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.66005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nakhonratchasima</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.66006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nokorn Nayok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.66008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phayathai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.90007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.90008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.90009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.90010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Headington, Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.44013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.46.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <results_first_submitted>May 4, 2012</results_first_submitted>
  <results_first_submitted_qc>May 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2012</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 2589 patients enrolled/randomised but only 2568 were treated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran 150 mg</title>
          <description>bid (twice daily) oral</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>PRN (as needed) to maintain an INR (international normalised ratio) of 2.0-3.0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1280">Started treatment.</participants>
                <participants group_id="P2" count="1288">Started treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1155">Completed planned observation time.</participants>
                <participants group_id="P2" count="1172">Completed planned observation time.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran 150 mg</title>
          <description>bid oral</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>PRN to maintain an INR of 2.0-3.0</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1280"/>
            <count group_id="B2" value="1288"/>
            <count group_id="B3" value="2568"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="16.19"/>
                    <measurement group_id="B2" value="55.1" spread="16.26"/>
                    <measurement group_id="B3" value="54.9" spread="16.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="499"/>
                    <measurement group_id="B2" value="512"/>
                    <measurement group_id="B3" value="1011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="781"/>
                    <measurement group_id="B2" value="776"/>
                    <measurement group_id="B3" value="1557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator assessed acute symptomatic deep vein thrombosis (DVT) of leg or pulmonary embolism (PE)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Symptomatic PE and symptomatic DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic PE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="877"/>
                    <measurement group_id="B2" value="873"/>
                    <measurement group_id="B3" value="1750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No PE and no DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE</title>
        <description>All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
        <time_frame>For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)</time_frame>
        <population>Full analysis set (FAS): consisted of all randomised patients who were documented to have taken at least one dose of study drug. Patients were assigned to the treatment groups as randomised, i.e. regardless of the actual medication taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE</title>
          <description>All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
          <population>Full analysis set (FAS): consisted of all randomised patients who were documented to have taken at least one dose of study drug. Patients were assigned to the treatment groups as randomised, i.e. regardless of the actual medication taken.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with event (up to day 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with event (up to end of ptp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio (HR) vs. Warfarin (events occurring between randomisation and end of ptp). The time to first occurrence of the primary endpoint was compared between treatment groups using the Cox proportional hazards (PH) model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin was set up to 2.75 for the HR analysis</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <p_value_desc>Non-inferiority P-Value.Two co-primary analyses performed on primary endpoint. Both non inferiority for the risk difference (RD) (at day 180) and for the HR (up to end of ptp) analyses to be reached in order to conclude positively on primary endpoint</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Patients without events are censored at the end of ptp.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RD vs. Warfarin for Proportion of patients with VTE or death related to VTE at 6 months. Point estimate and 95% CI for the overall RD obtained based on the Kaplan Meier (KM) estimates at 6 months (180 days) after adjusting for the stratification factors active cancer at baseline and symptomatic PE at baseline.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority margin was set up to 3.6% for the RD based on KM estimates</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Non-inferiority P-Value.Two co-primary analyses performed on primary endpoint. Both non inferiority for the RD (at day 180) and for the HR (events up to end of ptp) analyses to be reached in order to conclude positively on the primary endpoint.</p_value_desc>
            <method>Kaplan Meier weighted estimates</method>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HR vs. Warfarin (events occurring between randomisation and day 180). The time to first occurrence of the primary endpoint was compared between treatment groups using the Cox PH model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE. This analysis was performed as sensitivity analysis for statistical analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Symptomatic VTE and All Deaths</title>
        <description>VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
        <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Symptomatic VTE and All Deaths</title>
          <description>VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with event (up to day 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with event (up to end of ptp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RD vs. Warfarin for Proportion of patients with VTE or death at 6 months. Point estimate and 95% CI for the overall RD obtained based on the KM estimates at 6 months (180 days) after adjusting for the stratification factors active cancer at baseline and symptomatic PE at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6932</p_value>
            <method>Kaplan Meier weighted estimates</method>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HR vs. Warfarin (events occurring between randomisation and end of ptp). The time to first occurrence of the endpoint was compared between treatment groups using the Cox PH model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6383</p_value>
            <method>Regression, Cox</method>
            <method_desc>Patients without events are censored at the end of ptp.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Symptomatic DVT</title>
        <description>Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
        <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Symptomatic DVT</title>
          <description>Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with event (up to day 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with event (up to end of ptp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RD vs. Warfarin for Proportion of patients with symptomatic DVT at 6 months. Point estimate and 95% CI for the overall RD obtained based on the KM estimates at 6 months (180 days) after adjusting for the stratification factors active cancer at baseline and symptomatic PE at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1703</p_value>
            <method>Kaplan Meier weighted estimates</method>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HR vs. Warfarin (events occurring between randomisation and end of ptp). The time to first occurrence of the endpoint was compared between treatment groups using the Cox PH model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1054</p_value>
            <method>Regression, Cox</method>
            <method_desc>Patients without events are censored at the end of ptp.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Symptomatic Non-fatal PE</title>
        <description>Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
        <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Symptomatic Non-fatal PE</title>
          <description>Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with event (up to day 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with event (up to end of ptp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RD vs. Warfarin for Proportion of patients with symptomatic non-fatal PE at 6 months. Point estimate and 95% CI for the overall RD obtained based on the KM estimates at 6 months (180 days) after adjusting for the stratification factors active cancer at baseline and symptomatic PE at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2283</p_value>
            <method>Kaplan Meier weighted estimates</method>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HR vs. Warfarin (events occurring between randomisation and end of ptp). The time to first occurrence of the endpoint was compared between treatment groups using the Cox PH model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2101</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Due to VTE</title>
        <description>VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events.</description>
        <time_frame>From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Due to VTE</title>
          <description>VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with event (up to day 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with event (up to end of ptp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RD at 6 months vs. Warfarin for Proportion of patients who died due to VTE . Point estimate and 95% CI for the overall RD obtained based on the KM estimates at 6 months (180 days) after adjusting for the stratification factors active cancer at baseline and symptomatic PE at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0830</p_value>
            <method>Kaplan Meier weighted estimates</method>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died (Any Cause)</title>
        <description>Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
        <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died (Any Cause)</title>
          <description>Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with event (up to day 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with event (up to end of ptp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RD at 6 months vs. Warfarin for Proportion of patients who died from any cause. Point estimate and 95% CI for the overall RD obtained based on the KM estimates at 6 months (180 days) after adjusting for the stratification factors active cancer at baseline and symptomatic PE at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7348</p_value>
            <method>Kaplan Meier weighted estimates</method>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HR vs. Warfarin (events occurring between randomisation and end of ptp). The time to first occurrence of the endpoint was compared between treatment groups using the Cox PH model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8939</p_value>
            <method>Regression, Cox</method>
            <method_desc>Patients without events are censored at the end of ptp.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Symptomatic Fatal and Non-fatal PE</title>
        <description>Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
        <time_frame>For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Symptomatic Fatal and Non-fatal PE</title>
          <description>Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with event (up to day 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with event (up to end of ptp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RD vs. Warfarin for Proportion of patients with symptomatic fatal and non-fatal PE at 6 months. Point estimate and 95% CI for the overall RD obtained based on the KM estimates at 6 months (180 days) after adjusting for the stratification factors active cancer at baseline and symptomatic PE at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3210</p_value>
            <method>Kaplan Meier weighted estimates</method>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HR vs. Warfarin (events occurring between randomisation and end of ptp). The time to first occurrence of the endpoint was compared between treatment groups using the Cox PH model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3021</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MBE, MBE and/or CRBE, and Any Bleeding Events</title>
        <description>Major bleeding events (MBE) are defined as
Fatal bleeding
Symptomatic bleeding in a critical area or organ
Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells
Clinically-relevant bleeding events (CRBE) are defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding
gingival bleeding &gt;5 min
leading to hospitalisation and / or requiring surgical treatment
leading to a transfusion of &lt;2 units of whole blood or red cells
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
        <time_frame>From first intake of study drug to last intake of study drug + 6 days washout</time_frame>
        <population>Treated set (TS): consisted of all randomised patients who were documented to have taken at least one dose of study drug. Patients were assigned to the treatment groups as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MBE, MBE and/or CRBE, and Any Bleeding Events</title>
          <description>Major bleeding events (MBE) are defined as
Fatal bleeding
Symptomatic bleeding in a critical area or organ
Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells
Clinically-relevant bleeding events (CRBE) are defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding
gingival bleeding &gt;5 min
leading to hospitalisation and / or requiring surgical treatment
leading to a transfusion of &lt;2 units of whole blood or red cells
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
          <population>Treated set (TS): consisted of all randomised patients who were documented to have taken at least one dose of study drug. Patients were assigned to the treatment groups as treated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MBE and/or CRBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bleeding event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HR vs. Warfarin (events occurring between 1st intake of study drug and last intake of study drug + 6 days). The time to first occurrence of MBE was compared between treatment groups using the Cox PH model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>This is the analysis of the time to the first MBE.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HR vs. Warfarin (events occurring between 1st intake of study drug and last intake of study drug + 6 days). The time to first occurrence of any bleeding was compared between treatment groups using the Cox PH model, including the factors treatment, active cancer at baseline, symptomatic PE at baseline, and the interaction between active cancer and symptomatic PE.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
            <estimate_desc>This is the analysis of the time to the first occurrence of any bleeding event.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Coronary Syndrome (ACS)</title>
        <description>Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings.</description>
        <time_frame>From first intake of study drug to last contact date</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Coronary Syndrome (ACS)</title>
          <description>Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings.</description>
          <population>TS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During intake of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After stopping study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analyses</title>
        <description>Frequency of patients with possible clinically significant abnormalities.</description>
        <time_frame>From first intake of study drug to last intake of study drug + 6 days washout</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 150 mg</title>
            <description>bid oral</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>PRN to maintain an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analyses</title>
          <description>Frequency of patients with possible clinically significant abnormalities.</description>
          <population>TS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="1248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first intake of study drug to last intake of study drug + 6 days washout</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran 150 mg</title>
          <description>bid oral</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>PRN to maintain an INR of 2.0-3.0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Ileal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Behcet's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Purulent pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Radial nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Tracheal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Coagulation time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>International normalised ratio fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Osteodystrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Ovarian cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pseudomyxoma peritonei</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social problem</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intestinal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Tenotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Vascular compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1288"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

